Efficacy and Safety of Camrelizumab Plus Famitinib in Patients with Previously Treated Non-Small-cell Lung Cancer: a Single-Arm, Phase II Trial

Ming Gao,Xia Zhang,Huan Yan, Yan Zhao, Fang Yuan, Decong Sun, Xuejiao Yang,Yanfang Ju, Lijie Wang, Haitao Tao, Luyuan Tian, Changhong Zhao, Junxun Ma,Yi Hu,Zhefeng Liu

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY（2025）

Cited 0|Views1

Key words

camrelizumab,famitinib,NSCLC,PD-1 inhibitor,tyrosine kinase inhibitor

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined